Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Next Previous
Trial Profile

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; DSP 107 (Primary) ; Fruquintinib
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors KAHR Medical

Most Recent Events

  • 08 Jan 2026 According to a KAHR Bio media release, Company closed 22 Million USD financing to support this randomized Phase 2b trial.
  • 08 Jan 2026 According to a KAHR Bio media release, Interim results are expected in late 2026, with topline data anticipated in the second half of 2027.
  • 07 Jan 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top